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Abstract
Purpose The main objective of this present study was the investigation of potential novel transdermal patch technology (TEPI®)
delivering ibuprofen as the active pharmaceutical ingredient (API) using a novel poly(ether-urethane)-silicone crosslinked
pressure-sensitive adhesive (PSA) as the drug reservoir in a solvent-free manufacturing process.
Methods The patch was synthesized utilizing the hot-melt crosslinking technique without the addition of solvents at 80 °C in
100% relative humidity. Dissolution and permeation studies performed utilizing diffusion cells and subsequently HPLC validated
methods were employed to determine the API content in the acceptor solution. Accelerated stability studies were also performed
at 40 °C and 70% relative humidity. The adhesive performance of the fabricated patch was evaluated utilizing loop tack adhesion
tests.
Results In vitro permeation experiments across both Strat-M® and human skin demonstrated that ibuprofen can easily be
released from the adhesive matrix and penetrate through the studied membrane. A comparison on the permeation rates of the
API across the two membranes indicated that there is not a strong correlation between the obtained data. The presence of
chemical enhancers facilitated an increased flux of the API higher than observed in the basic formulation. Initial stability studies
of the optimized formulation showed no degradation with respect to the drug content. Adhesion studies were also performed
indicating higher values when compared with commercially available products.
Conclusions The present study demonstrated the fabrication of an ibuprofen patch utilizing a versatile, solvent-free drug delivery
platform. Upon optimization of the final system, the resulting patch offers many advantages compared to commercially available
formulations including high drug loading (up to 25 wt%), good adhesion, and painless removal leaving no residues on the skin.
This PSA offers many advantages over existing adhesive technology.
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Introduction
Transdermal drug delivery was first introduced commercially
in 1979 with the scopolamine patch, and since then, it has
been an attractive route for drug delivery as well as a chal-
lenging area of research. Topical delivery offers compelling
advantages in comparison with more conventional delivery
systems as it provides many advantages over conventional
routes by enhancing patient compliance, avoiding first-pass
metabolism, and minimizing harmful side effects due to over-
dose [1]. Additionally, it can address the limited controlled
release and the low bioavailability of many oral drugs
avoiding a potential damage to the gastrointestinal tract.
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Transdermal delivery systems can also be preferred as they are
non-invasive, self-administered, and generally inexpensive
[2–4]. Hence, over the past few years, many drugs (including
nicotine, lidocaine, methyl salicylate, hormones, and fentanyl)
have been utilized for the development of transdermal patches
to treat various conditions.
A main disadvantage of drug delivery patches is that they
are frequently unable to convey the desired active ingredient
through the skin, as it is well established that the major pene-
tration barrier resides within the stratum corneum [5–7]. Its
complex structure forces the permeant to travel between mul-
tiple hydrophilic and hydrophobic domains which is unfavor-
able in most cases [8]. Consequently, the drug employed
should be relatively both hydrophilic and hydrophobic to suc-
cessfully penetrate the skin. Non-steroidal anti-inflammatory
drugs (NSAIDs) are good candidates as they often have low
molecular weights with appropriate physicochemical proper-
ties and their transdermal delivery has already been reported
[9–11]. Ibuprofen is one of the most prominent drug among
NSAIDs and is routinely employed to ease moderate pain,
reduce swelling, control fever, and treat arthritis at higher
doses [12–15]. However, along with most of other NSAIDs,
ibuprofen has risks and complications including inflammation
of the stomach (gastritis) which may result in a stomach ulcer
or even bleeding [16, 17].
Transdermal systems can modulate the drug release levels
on site for long periods of time but the absolute amount per-
meating the skin is strongly dependent upon the matrix in
which the active drug is applied. Various polymers are rou-
tinely employed as the adhesive matrix including cellulose
derivatives, chitosan, polyacrylates, polyurethanes, and
silicone-based polymers [18–20]. Regardless its chemical na-
ture, the adhesive must cause no skin irritation and sensitiza-
tion during skin contact, provide sufficient adhesion to ensure
optimum dosage, and be easily removed without leaving any
residues on the skin. Among the available systems, silicon-
based pressure-sensitive adhesives (PSAs) are of interest
mainly due to their low irritation, good skin adhesion, and
favorable diffusion characteristics for many APIs [21–23].
However, typical PSA systems employ volatile organic sol-
vents (VOCs) raising environmental and financial concerns.
Stemming from these concerns, various solvent-free delivery
systems have been introduced to eliminate VOC emissions
and possibly provide properties to extend the use of these
materials to new applications [23]. Hot-melt silicone-based
PSAs (HMPSAs) offer many advantages as they are less ex-
pensive, they can be softened to viscosities suitable for coating
and then return to a flawless state upon cooling. Moreover,
they can be formulated to contain little or no chemical func-
tionality reducing the possibility of interactions with the API
[24] making these systems a very attractive option for medical
applications.
In this present study, a novel TEPI® transdermal patch
technology is reported and is exemplified with ibuprofen as
the active pharmaceutical ingredient (API) and a newHMPSA
crosslinked polymer excipient as a drug reservoir. No volatile
solvents are employed in any stage of the patch production
with all added components present in the final device. The
API release from the new PSA was studied employing non-
rate-limiting membranes. Both synthetic [25, 26] and natural
membranes were employed to assess permeability of the API
and in vivo performance over a 24-h period employing diffu-
sion cells. A brief comparison between these membranes was
also reported. Chemical enhancers (low molecular weight ex-
cipients) were added in to the formulation to increase skin
permeability enabling molecular transport of the API across
human skin membranes [8, 27–29]. The final, optimized sys-
tem offers many advantages compared to commercially avail-
able formulations including high loading, good adhesion.
Finally, accelerated stability studies at 40 °C and 70% relative
humidity suggested that the optimized formulation is stable
with respect to its drug content, adhesion, and physical
characteristics.
Materials and Methods
Materials
All materials were used as received unless otherwise stated.
Ibuprofen (Ph. Eur. S380) was purchased from Shasun
Pharmaceuticals (Chennai, India). The pre-cured adhesive
matrix utilized in all the patches was provided by Bostik
(Cedex, France). Titanium n-butoxide, benzyl alcohol (BA),
di(ethylene) glycol monoethyl ether (DEGEE), propylene gly-
col (PG), polyethylene glycol 400 (PEG400), oleic acid (OA),
octadecanol (OD) phosphate buffer saline (PBS, pH 7.4), and
trifluoroacetic acid (TFA) were purchased from Sigma-
Aldrich in the highest available grade. HPLC gradient grade
water and acetonitrile (MeCN) were also purchased from
Sigma-Aldrich. Strat-M® membrane was purchased from
Merck Millipore. Nylon (0.45 μm pore size) membrane was
purchased from Fisher Scientific. Human male or female ab-
dominal skin samples (400 ± 50 μm) were sourced fresh from
a licensed company in strict accordance with the Human
Tissue Act 2004 and Human Tissue Regulations 2007 and
codes of practice.
Instrumentation
The HPLC (Agilent 1220 Infinity LC equipped with variable
wavelength detector) was fitted with a Phenomenex Kinetex®
EVO column, 5 μm C18 (l = 50 mm; ∅ = 4.6 mm) with
Security Guard ULTRA guard cartridge (P/N AJ0-9296).
Patches were fabricated using a coater purchased from RK
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Print Coat Instruments Ltd. (K Control Coater K101). The
coater is equipped with a heated bed and a bar coating head
which uses a push bar to drive a gap applicator along the
substrate being coated. A micrometer adjustable spreading
blade was used to accurately set the substrate/blade gap up
to 10,000 μm in 10 μm increments.
HPLC Validation
A validated reverse phase HPLC methodology was used to
determine the content of the API in the acceptor medium.
Detection was achieved using a spectrophotometer at λ =
264 nm. The flow rate of the eluent was set to 1.0 mL min−1
and all injections of 50 μl. Data was collected and analyzed
using Agilent Technologies OpenLAB CDS software (version
C.01.07 [27]). Mobile phase solvents used were HPLC grade
and consisted of mobile phase (a) 100% v/v water, 0.1% TFA;
mobile phase (b) 100% v/v MeCN. The calibration curve for
ibuprofen was linear at concentrations ranging from 1 to
50 μg mL−1. The accuracy of the assay was tested by triplicate
injection of five samples within 50–200% range of nominal
concentration (50 μg mL−1), and subsequent calculation of the
recovery percent. Estimated average values of recovery and
RSD were found to meet accuracy criteria of 100 ± 2% and <
1%, respectively. The limit of detection (LOD) was defined as
lowest amount of ibuprofen which can be reproducibly detect-
ed as the signal which is three times higher than the baseline
and was found to be 200 ng mL−1. The limit of quantification
(LOQ) was defined as the lowest amount of analyte which
reproducibly gives signal-to-noise ratio (SNR) of 10/1 and
was found to be 600 ng mL−1.
Ibuprofen Patch Preparation and Curing Process
All formulations were prepared using mass fractions of ingre-
dients. Initial experiments employed the basic formulation
(API, curing catalyst, and benzyl alcohol) without the addition
of any penetration enhancers. A short optimization excipient
study resulted in the optimized formulation given in Table 1.
The adhesive matrix was charged in a reactor equipped with
an overhead stirrer and was heated to 80 °C under inert atmo-
sphere. Subsequently, a mixture of the curing catalyst, benzyl
alcohol, and the permeation enhancers was added in the reac-
tor and the mixture was left to stir at 300 rpm for 5 min.
Ibuprofen and oleic acid were added next and the mixture
was left to stir for further 5 min before it was cast on a release
liner and spread uniformly utilizing an automated film coater.
The resulting film was subsequently heated in an oven at
75 °C in 100% humid atmosphere for 4 min. A backing layer
was added onto the surface upon completion of the curing.
Drug Content/Extraction
Discs were cut from the test patch using a die cut punch, 8 mm
(0.50 cm2) and the weight recorded. Upon removal of the
release liner, the disc was placed into a vial equipped with a
stirrer and 10 mL of MeCN:H2O (50:50 v/v) solution was
added. The mixture was left for 24 h at 60 rpm. Using a
syringe, approximately 1 mL was extracted from the sample
vial and dispensed through a filter into a 2 mL HPLC vial. A
validated HPLC method was then used to determine the ibu-
profen content. The above procedure was repeated in 12 rep-
licates to ensure repeatability of the results.
Permeation and Release Studies
Samples were cut to size and applied to the membranes (Strat-
M and human skin were used for permeation, nylon was used
for release experiments) at ambient temperature. Upon appli-
cation, patches were placed into jacketed diffusion cells (A =
1 cm2). Prior to the start of the experiment, the acceptor solu-
tion (PBS:Transcutol, 90:10 v/v) was equilibrated at 32 ± 1 °C
for 15min bymaintaining the jacket temperature at 36 °C. The
acceptor medium was stirred at 600 rpm throughout the ex-
periment. Samples were taken at regular intervals and ana-
lyzed using the HPLC validated method. Six diffusion cells
were employed in parallel for each formulation. Reported cu-
mulative amounts and flux values represent the mean of six
measurements (n = 6).
Adhesion Studies
The adhesion of patches was determined using a
Mecmesin MultiTest 2.5-d+ testing system equipped with
an Advanced Force Gauge 50N. The instrument was set
up in accordance with the manufacturer’s guidelines to
perform loop tack tests. Samples were cut to 175 ×
25 mm. Stainless steel was employed as the substrate.
The maximum peak force (N) required to detach a patch
from the substrate was taken as the evaluation parameter.
Table 1 List of components used for the synthesis of the optimized
formulation for the ibuprofen patch
Ingredients Function Mass fraction, wt%
Adhesive Adhesive matrix 75.00
Ibuprofen API 10.00
Titanium n-butoxide Curing catalyst 1.50
Benzyl alcohol Co-solvent 2.00
DEGEE Permeation enhancer 5.00
PG 5.00
Oleic acid 1.50
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An average of three measurements (n = 3) was accepted as
a statistically robust value of adhesion.
Stability Studies
Short-term stability studies of the optimized formulation per-
formed at 40 °C and 70% relative humidity to confirm the
stability of the API in the formulation. Parameters determined
during the stability study included extraction studies and vi-
sual inspection. The patches were stored in aluminum pouches
prior to testing. Samples were withdrawn periodically and
evaluated for the different points of analysis utilizing HPLC
validated methods and visual inspection.
Results and Discussion
Compatibility of Ibuprofen with the TEPI® System
The pressure-sensitive adhesive (PSA) employed consists of a
proprietary poly(propylene glycol)-based polyurethane (PPG-
PU) with trimethoxysilane (SiOMe3) terminal functional
groups (a silylated polyurethane, SPUR). Upon contact with
moisture, SiOMe3 undergoes a condensation (curing) reaction
to form a crosslinked polymer matrix with the release of meth-
anol. The maximum theoretical amount of residual methanol
is 0.5 wt% relative to the mass of the adhesive. However, the
curing temperature is 10 °C higher that the boiling point of
methanol (65 °C) resulting in small amounts present within
the formulation.
The PSA formulation can be loaded with an API and ap-
propriate excipients by solubilization prior to cure to give
homogeneous PSA films, Fig. 1. No additional volatile sol-
vent is added in any of stage of this process.
As ibuprofen is present in the PSA during curing, it is
important to investigate any influence it may have on the
curing process. Namely, the formation of by-products of ibu-
profen and PPG-PU and stability of the API under the curing
conditions. In order to verify that ibuprofen (wt% between 10
and 20) does not interact with the adhesive in an irreversible
way and/or degrade during the PSA cure, simple mass balance
calculations were employed. The method is based on a com-
parison of theoretical and actual mass fractions of ibuprofen in
fabricated patches. A theoretical dose of ibuprofen in patches
(Dth) can be estimated using eq. 1.
Dth: ¼ Ms  FAPIA ð1Þ
where Dth.—theoretical dose per cm
2, Ms—mass of sample,
FAPI—mass fraction of API in formulation, A—area of sample
in cm2.
An actual dose (Da) was determined by submerging samples
into 10 mL of acetonitrile/water mixture for 24 h, which was
then assayed using the validated HPLC method for ibuprofen.
The obtained results for three ibuprofen formulations are given
in Table 2. An average of 12 measurements for each formula-
tion was accepted as a statistically reliable value. A relative
standard deviation of 10% was taken into account as an accep-
tance criterion according to the European Pharmacopoeia.
The recovery values show that the mass balance of ibupro-
fen is conserved within the analytical error margin. The ob-
tained HPLC traces correspond to the mass balance evaluation
revealing no additional peaks (Fig. 2). Therefore, ibuprofen
does not form side products with the reactive PPG-PU and/or
degrade during the cure process.
Further analysis on the fabricated patches with various wt%
of ibuprofen included uniformity of the product, permeation
using a rate-limiting membrane, adhesion, and market require-
ments. Examples can be found in Figs. S1 and S2 and Table S1.
However, for the final formulation, 10 wt% of the API was
employed to simulate existing commercial products and to en-
sure a local pain treatment other than a systemic delivery.
API Release from the Patch
The drug release characteristics of the basic formulation (no
added excipients) were studied in vitro using artificial non-
rate-limiting membranes. This study allows for confirmation
that the cured adhesive is a reservoir for ibuprofen and does
not limit its use as a transdermal drug delivery system. These
experiments can be performed using non-rate-limiting mem-
branes, including porous silicone, nylon, or PTFE. In this
study, nylon was employed as the test model membrane for
a passive release. The studied formulation contained 10 wt%
of API (patch thickness 160 μm) without adding any perme-
ation enhancers. Patches are approximately 12 × 8.5 cm with
10 mm corner fillet radius (101 cm2). A mixture of
DEGEE:PBS (10:90) was employed as the acceptor solution
and the temperature maintained at 32 ± 1 °C. Samples were
taken periodically for a total period of 24 h. It must be noted
that hydrophobic drugs such as ibuprofen have a limited sol-
ubility in aqueous media (e.g., PBS buffer), which limits the
flux by a quick saturation of the acceptor solution. Hence, a
small amount of DEGEE (10%) solution to help circumvent
this saturation issue.
The data depicted in Fig. 3 clearly shows that there is no
physicochemical barrier for ibuprofen being released from the
patch. A total of 1.5 mg cm−2 of ibuprofen was released from
the patch over 12 h, which is equal to the applied dose. Thus,
ibuprofen can be released from TEPI® patches which make
them excellent candidates for a PSA reservoir for a transder-
mal drug delivery system.
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API Permeation
Comparison of Synthetic Membranes and Human Skin
Initial studies for assessing ibuprofen permeability employed
MerckMillipore Strat-M, a synthetic non-animal-basedmodel
for predictive diffusion in human skin. There is a correlation
tool on a dedicated website allowing a comparison with hu-
man skin for selected APIs, indicating that permeation profiles
can vary depending on the drug. However, there is no corre-
lation data available for ibuprofen. Thus, a comparison on the
permeation rates of the basic formulation (10 wt% API,
160 μm thickness) across Strat-M and human skin was con-
ducted. The cumulative permeated amount for Strat-M after
24 h was found to be 109.47μg cm−2, whereas for human skin
was 85.73 μg cm−2 for the same period (Table 3, Fig. 4). Both
membranes resulted in similar flux value in 24 h
( 4 μg cm−2 h−1) (Table 3). It was therefore concluded that
Stat-M shows some correlation for the pure formulation.
Interestingly, in the presence of excipients, there is no corre-
lation between the two different membranes. Two formula-
tions including F1 mixtures of glycol (DEGEE:PG = 5:5)
and F2 mixtures of glycols with fatty compounds
(DEGEE:PG:OD = 5:5:3) resulted in almost seven times
higher cumulative amounts and approximately five times
higher flux values for Strat-M when compared with human
skin (Figs. S3 and S4). Thus, for all the following studies,
human skin was employed as the studied membrane to ensure
credibility of the results.
Optimized Formulation and Impact of Excipients on Patch
Adhesion
Skin permeability is a complex phenomenon depending on
chemical and physical properties of each API. For instance,
transdermal delivery of nicotine achieves a therapeutic
Table 2 Comparison of
theoretical and actual doses of
ibuprofen in TEPI® patches
Parameter Dth., mg cm
−2 Da [HPLC], mg cm
−2
API, wt% 10 15 20 10 15 20
S1 1.63 2.67 3.30 1.52 2.47 3.50
S2 1.71 2.25 3.43 1.66 2.27 3.26
S3 1.62 2.25 3.03 1.83 2.20 3.16
S4 1.35 2.37 2.76 1.51 2.30 2.84
S5 1.42 1.97 2.98 1.40 2.07 3.04
S6 1.34 2.25 3.82 1.40 2.12 3.62
S7 1.38 2.22 2.93 1.46 2.16 2.98
S8 1.62 2.14 3.37 1.56 2.09 3.20
S9 1.73 2.46 3.11 1.77 2.28 3.03
S10 1.54 2.25 2.97 1.56 2.17 3.10
S11 1.61 2.49 3.08 1.61 2.52 3.07
S12 1.45 2.49 3.61 1.45 2.46 3.65
Average 1.53 ± 0.14 2.32 ± 0.19 3.20 ± 0.31 1.56 ± 0.14 2.26 ± 0.15 3.20 ± 0.26
Relative standard deviation, % 8.79 6.80 8.04
Mean recovery from theoretical, % 102 98 100
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Fig. 1 Mechanism of polymer matrix formation
concentration in blood plasma, while ibuprofen topical formu-
lations (gels, creams etc.) are used for a local pain treatment
only. In many cases, in order to help overcome the skin barrier
and deliver a required amount of API, formulations are en-
hanced with excipients. For example, commercially available
ibuprofen gels/creams usually contain alcohols (ethanol or
isopropanol) which facilitate an effective API permeation
through the skin. As it can be seen from Figs. 3 and 4, the
release and permeation profiles are very different for the ibu-
profen patch which can be explained by the skin barrier. There
are many permeation enhancers reported in literature, which
have different mechanisms of action [30]. Interestingly, com-
monly employed glycols have been reported to show
synergistic actions when combined with fatty compounds
which allows for a higher flux of, mainly hydrophobic, APIs
across a studied membrane. To exemplify the possibility to
employ these mixtures with the TEPI® drug delivery system,
we prepared ibuprofen patches with various excipient formu-
lations keeping any the other variables constant (10 wt% API,
160 μm thickness). The basic formulation (no excipients) was
employed for a comparison.
Commonly employed glycol mixtures (5:5 wt%) including
DEGEE, PG, PEG400 combined with fatty compounds were
investigated mainly due to their chemical properties and low
toxicity. Octadecanol and oleic acid were employed as the
fatty compounds. Oleic acid is one of the leading penetration
43
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b
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Fig. 2 Expanded HPLC traces. a
*Ibuprofen extracted from cured
patches. b *Representative peak
of pure ibuprofen
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Fig. 3 Release of ibuprofen from
10 wt% patches. A mixture of
PBS/Transcutol (90/10 v/v) was
used as the acceptor solution
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enhancers used for transdermal applications, and as a fatty
compound, it can act synergistically with glycols, when it is
employed in small concentrations, to increase the flux of lipo-
philic APIs. Detailed mechanistic studies have revealed that
oleic acid pools in the stratum corneum increases bilayer flu-
idity. The results for these combinations can be found in
Table 4 and Fig. 5. A detailed summary of the formulations
employed can be found in Table S2). Combination of various
glycols with oleic acid resulted in higher flux values if com-
pared to the equivalent mixtures with octadecanol. Both for-
mulations including oleic acid resulted in very similar perme-
ated amounts (> 220 μg cm−2) over a 24 h period. However,
the formulation without PEG400 showed constant flux values
over the total time period of the study, and thus, we decided
that the best formulation for ibuprofen 10 wt% is DEGEE:
PG: OD (5:5:1.5).
An important characteristic of any transdermal patch is
effective adhesion. An overall drug delivery performance of
a patch depends on its area, and therefore, a detached surface
will reduce the amount of API permeated across the skin. This
becomes more pronounced when a patch needs to be worn for
a long period of time, e.g., 7 days. To overcome these issues, a
patch should strongly adhere to the skin over the entire period
of application. Therefore, the impact of the various excipient
mixtures on the adhesion of the resulting patch was assessed
(Fig. 6). The adhesion of the pure formulation showed (as
expected) the highest adhesion (~ 9 N). Upon addition of ex-
cipients, the adhesion dropped approximately two times (~
5 N) but maintained within a similar range for all studied
formulations (4.5–5.8 N). Commercially available patches
were employed as a comparison. Figure 6 illustrates that
TEPI patches have a significantly higher adhesion in compar-
ison to patches currently available in the UK market. It must
be noted that the high adhesion values obtained for the TEPI
patches still allow for a painless removal and considered to be
within an acceptable range if compared to commercially avail-
able adhesive medical tapes who resulted in a maximum peak
~ 4 N.
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Fig. 4 Human skin and Strat-M
permeation profiles for ibuprofen
10 wt%, 160 μm patch thickness
Table 3 Comparison of Strat-M
and human skin on permeation
rates of ibuprofen
Membrane API
(wt%)
Formulation
(wt%)
Permeated amount in 24 h
(μg cm−2)
Flux in 24 h
(μg cm−2 h−1)
Strat-M 10 Basic* 109.47 4.96
F1 584.61 20.06
F2 883.87 29.31
Human skin Basic* 85.73 4.20
F1 81.21 3.78
F2 118.61 5.93
*No excipients were employed for the basic formulation. However, 2 wt% of BAwas employed in both cases to
enhance the API solubility in the adhesive matrix
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Table 4 Impact of enhancers on
the drug delivery performance of
TEPI ibuprofen 10 wt% patches
No Formulation
(wt%)
Permeated amount in
24 h
(μg cm−2)
Flux in 24 h
( μ g
cm−2 h−1)
Delivered in
24 h
(%)
F3 Basic (no excipients) 85.73 4.20 5.4
F4 DEGEE: PG: OD (5:5:1.5) 183.35 6.86 11.2
F5 DEGEE: PG: PEG400: OD
(5:5:2.5:1.5)
146.95 6.32 8.1
F6 DEGEE: PG: OA (5:5:1.5) 226.90 10.09 17.3
F7 DEGEE: PG: PEG400: OA
(5:5:2.5:1.5)
222.65 9.06 13.6
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Stability Study for the Optimized Formulation
A short-term stability study (3 months) for the optimized for-
mulation was also performed to assess the quality and estimate
the shelf-life of the resulting patch. Patches are approximately
12 × 8.5 cm with 10 mm corner fillet radius (101 cm2). This
study was outsourced and took place under Good Laboratory
Practice, GLP conditions (40 °C and 70% relative humidity).
Storage under these conditions showed that ibuprofen trans-
dermal patches based on TEPI® technology are stable.
Samples were evaluated for crystallinity of the API and deter-
mination of the dose by an extraction method utilizing vali-
dated HPLC methods. Formation of ibuprofen crystals was
not observed and equal amounts of ibuprofen were extracted
from the patches after 1, 2, and 3 months of storage (Fig. 7,
Table 5, Fig. S5).
Conclusions
In this study, the use of novel, solvent-free transdermal drug
delivery system has been investigated. TEPI® system can be
utilized as a drug reservoir for ibuprofen allowing for control
of the API dose per area within analytical error margin. It was
found that ibuprofen can easily be released from fabricated
patches and penetrate through human skin membranes. The
flux of API across the membranes can be controlled by includ-
ing permeation enhancers. The adhesion of TEPI ibuprofen
patches was also assessed and it was significantly higher if
compared to products available on the market. Interestingly,
although the presence of enhancers in our formulations had a
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Fig. 7 Images illustrating the stability of TEPI® ibuprofen patches
Table 5 Stability study of the optimized formulation under GLP
conditions at 40 °C and 70% RH
Time (months) Extracted mass, μg Extracted mass per area, μg cm−2
0 1240 2480
1 1230 2460
2 1256 2512
3 1229 2458
Average 1238.75 2477.5
RSD, % 1.01 1.01
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significant impact on the adhesion, the resulting patches had
notably high adhesion values when compared to commercial
products. Finally, initial studies on the stability of the opti-
mized formulation suggested that the ibuprofen patch is stable
under accelerated temperatures and no change in the physical
characteristics has been observed.
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